This project is designed to evaluate the molecular markers in patients that are undergoing radiotherapy in serum and urine. This work is prospective and hypothesis generating. In the previous year we have initiated an international trial of patients with GBMs to determine if urinary VEGF or MMP-2 can help predict outcome. We have collected 34 first samples and expect to collect the 140 samples within the next year. This past year we have worked on standardizing the collection procedures, analysis procedures and the many biomolecules that could incorrectly alter the VEGF levels and have recently sent those manuscripts out for review.
| Russo, Andrea L; Jedlicka, Kimberly; Wernick, Meredith et al. (2009) Urine analysis and protein networking identify met as a marker of metastatic prostate cancer. Clin Cancer Res 15:4292-8 |
| Simone, Nicole L; Menard, Cynthia; Soule, Benjamin P et al. (2008) Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in Quality of Life measured by EPIC score. Int J Radiat Oncol Biol Phys 70:90-5 |
| Russell, Jeffery S; Brady, Kristin; Burgan, William E et al. (2003) Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res 63:7377-83 |
| Camphausen, Kevin; Moses, Marsha A; Menard, Cynthia et al. (2003) Radiation abscopal antitumor effect is mediated through p53. Cancer Res 63:1990-3 |
| Chan, Linda W; Camphausen, Kevin (2003) Angiogenic tumor markers, antiangiogenic agents and radiation therapy. Expert Rev Anticancer Ther 3:357-66 |
